TECXNasdaq

Tectonic Therapeutic, Inc.

Healthcare·Cardiovascular·Phase 2·Watertown, MA, United States
CardiovascularRespiratory

Tectonic Therapeutic, Inc. (TECX): 5 pipeline candidates · ~39 mo cash runway · 2 clinical trials. Updated within the last hour.

7.5/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

38.8 months

Financial Health9.9

D/E 0.07 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider Signal3.1

2 buys · 7 sells (180d)

A transparent, data-derived signal for Tectonic Therapeutic, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$556.8M

Cash

$237.4M

Quarterly Burn

$18.4M

Runway

38.8 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2029
Today~43 mo out
Catalyst within runway

Pipeline (5 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

108

Total value held

$321.2M

HolderSharesValue
fmr llc2,816,494$87.1M
vanguard capital management llc947,064$29.3M
blackrock, inc.860,352$26.6M
braidwell lp847,151$26.2M
baker bros. advisors lp607,788$18.8M
susquehanna international group, llp293,475$9.1M
kennedy capital management llc286,682$8.9M
geode capital management, llc268,273$8.3M
marshall wace, llp229,595$7.1M
orbimed advisors llc226,600$7.0M

Showing top 10 of 108 institutional holders of Tectonic Therapeutic, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

2 clinical trials·CEO: Dr. Alise S. Reicin M.D., Ph.D.

Frequently asked questions

How many drug candidates are in Tectonic Therapeutic, Inc.'s pipeline?

Tectonic Therapeutic, Inc. (TECX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Tectonic Therapeutic, Inc.'s lead drug candidate?

Tectonic Therapeutic, Inc.'s most advanced tracked candidate is tx000045 (Phase 2) for Hypertension, Pulmonary.

What is Tectonic Therapeutic, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Tectonic Therapeutic, Inc. has approximately 38.8 months of cash runway.

What is Tectonic Therapeutic, Inc.'s market capitalization?

Tectonic Therapeutic, Inc.'s market capitalization is approximately $556.8M.

Who is the CEO of Tectonic Therapeutic, Inc.?

Dr. Alise S. Reicin M.D., Ph.D. is the chief executive officer of Tectonic Therapeutic, Inc. (TECX).

Get the full picture on Tectonic Therapeutic, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.